

**REVIEW ARTICLE ON ROLE OF PHARMACIST IN ADR  
MONITORING**

**Dr. Sreejanya Mohan\*, Dr. Ajith Babu T. K., Ayshan Jahan Sirin and Fathimath  
Irfana K. M.**

India.

Article Received on  
27 August 2024,

Revised on 17 Sept. 2024,  
Accepted on 07 October 2024

DOI: 10.20959/wjpr202420-34196



**\*Corresponding Author**  
**Dr. Sreejanya Mohan**  
India.

**ABSTRACT**

ADRs are a significant concern in healthcare, causing morbidity, mortality and increased healthcare costs. Pharmacist play a vital role in ADR monitoring, ensuring patient safety and optimizing therapy. Integration of pharmacists into healthcare teams is essential for optimizing patient safety and therapy outcomes.

**KEYWORDS:** Adverse drug reactions, pharmacist, patient safety, medication monitoring, pharmacovigilance.

**INTRODUCTION**

When treating patients with drug, the goal is to utilize the most effective agent to treat a condition while minimizing hazards of therapy. These hazards are usually known as adverse drug reactions (ADRs). WHO defined ADRs as unintended and undesired harmful effects of agents administered at doses normally used in humans for diagnostic, prophylactic, therapeutic use or for the modification of the physiological function.<sup>[1]</sup>

Spontaneous reporting system (SRS) is the most widely used system globally to report adverse reactions by health care professionals, drug companies, or patients themselves to the national authorities regulating PV activities in the country.<sup>[2]</sup> SRS could improve the safety profile of a particular drug by detecting and reporting ADRs that may not have been detected during premarketing clinical trials or even during post-marketing surveillance.<sup>[3,4]</sup>

**ROLE OF PHARMACIST IN ADR MONITORING**

The role of pharmacists in ADR reporting has evolved over the past decade but still vary

geographically.<sup>[5,6]</sup> The variation in the role of pharmacists in PV activities can be explained by the variations in pharmacists' role within health care system across the globe from mere "dispenser" to the guardian of drug safety and patient outcomes. As the role of pharmacists within the health care systems continues to evolve, their role in ADR reporting is getting recognized. Research evidence shows that recruitment of pharmacists in public hospitals can not only detect and report ADRs but also prevent ADRs and reduce associated humanistic and financial costs.<sup>[7,8]</sup> This could be explained by the fact that pharmacists with a clinical background have greater awareness about ADR reporting system and are frequently engaged with prescribers.<sup>[9]</sup> Furthermore, regular contact with the patients coupled with the access to patient's medical records allow clinical pharmacists at the hospitals to develop a better understanding of the suspected ADRs.<sup>[10]</sup>

### **ROLE OF PHARMACIST IN REPORTING ADR**

ADR reporting by pharmacists is a crucial part of the drug safety process.<sup>[11]</sup> Thanks to a pharmacy-based ADR reporting system, the number of ADR reports increased 8-fold through in the United Kingdom (UK).<sup>[12]</sup> The ADR reporting by hospital pharmacists significantly enhanced the UK Yellow Card Scheme, the nation's PV programme.<sup>[13]</sup>


Spontaneous reporting of suspected ADRs is the key feature of PV.<sup>[14]</sup> With round the clock observation of inpatients, the hospital setting is very favorable in detecting and reporting the signals for ADRs.<sup>[15]</sup>

Under-reporting of ADRs is a cause to concern.<sup>[16,17]</sup> ADR under-reporting could be decreased through educational interventions.<sup>[18]</sup> Providing customized trainings and educational sessions would help to improve ADR reporting. It has also been suggested that a hospital written policy on PV would certainly add value in the process of detecting and reporting ADRs.<sup>[19]</sup> Hospital pharmacists should be taught with the value of ADR reporting which would alter their attitude towards a social responsibility.<sup>[20,21]</sup>

### **BARRIERS TOWARDS ADR REPORTING**

With round the clock observation of the inpatients, the hospital setting is very favorable in detecting and reporting the signals for ADRs. With round the clock observation of the inpatients, the hospital setting is very favorable in detecting and reporting the signals for ADRs. Given that both community and hospital pharmacists can play an important role in ADR reporting, a number of studies have been conducted globally to evaluate knowledge,

attitudes, and practices of pharmacists toward ADR reporting with an aim to identify knowledge, attitudes, practices, and barriers to ADR reporting, so that appropriate interventions can be designed and implemented to overcome these barriers.<sup>[22,23]</sup>



The uncertainty of pharmacists toward ADR reporting could have been influenced by their lack of awareness about ADR reporting. Furthermore, pharmacists may be reluctant to report minor reactions and would only report an ADR once they have established the association of the ADR with the suspected drug.<sup>[24]</sup>

## STRATEGIES TO IMPROVE ADR REPORTING

As a broad principle, strategies for improving ADR reporting should be targeted both at the health care system level and individual pharmacist level. In addition to encouraging pharmacists to report ADRs, their knowledge and skill deficits in detecting and reporting ADRs should also be fulfilled through continuous professional development programs.<sup>[25,26]</sup>

On health-system level, to engage community pharmacists more in ADR reporting, providing community pharmacists with access to patient's medical and medication history will enable pharmacists to establish ADR causation and report ADRs as inability to establish causation

deter pharmacists from reporting ADRs. Research evidence suggests that electronic ADR tools can also improve spontaneous reporting of ADRs.<sup>[27,28]</sup>

## REFERENCE

1. Fathi Mohamed Sherif, Pharmacy & Pharmacology International Journal, Role of the pharmacist in adverse drug reaction monitoring, 2017; 5(5): 172.
2. Pal SN, Duncombe C, Falzon D, Olsson S. WHO strategy for collecting safety data in public health programmes: complementing spontaneous reporting systems. *Drug Saf.*, 2013; 36(2): 75–81.
3. Rossi AC, Knapp DE, Anello C, et al. Discovery of adverse drug reactions. A comparison of selected phase IV studies with spontaneous reporting methods. *JAMA.*, 1983; 249(16): 2226–2228.
4. Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. *Drug Saf.*, 2006; 29(5): 385–396.
5. Van Grootheest K, Olsson S, Couper M, de Jong-van den Berg L. Pharmacists' role in reporting adverse drug reactions in an international perspective. *Pharmacoepidemiol Drug Saf.*, 2004; 13(7): 457–464.
6. Osemene KP, Ayeni MI, Afolabi MO. The role of community pharmacists in monitoring adverse drug reactions in Nigeria. *J Pharm Health Serv Res.*, 2012; 3(4): 197–204.
7. Roberts PI, Wolfson DJ, Booth TG. The role of pharmacists in adverse drug reaction reporting. *Drug Saf.*, 1994; 11: 7–11.
8. Glassman P. *Making Health Care Safer II: An Updated Critical Analysis of the Evidence for Patient Safety Practices*. Rockville, MD: agency for Healthcare Research and Quality; (US): 2013. Mar, Clinical pharmacist's role in preventing adverse drug events: brief update review. (Evidence Reports/Technology Assessments, No. 211). Chapter 4.
9. Calvert RT. Clinical pharmacy—a hospital perspective. *Br J Clin Pharmacol.*, 1999; 47(3): 231–238.
10. Schlienger RG, Lüscher TF, Haefeli WE, Schoenenberger RA. Academic detailing improves identification and reporting of adverse drug events. *Pharm World Sci.*, 1999; 21(3): 110–5.
11. Gavaza P, Brown CM, Lawson KA, Rascati KL, et al. Examination of pharmacists' intention to report serious adverse drug events (ADEs) to the FDA using the theory of planned behavior. *Res Social Adm Pharm.*, 2010 Nov 3.

12. Winstanley PA, Irvin LE, Smith JC, Orme ML, Breckenridge AM. Adverse drug reactions: a hospital pharmacy-based reporting scheme. *Br J Clin Pharmacol*, Jul. 1989; 28(1): 113-6.
13. Anne Leea, D Nicholas Bateman, Clive Edwards, James M Smith, Michael D Rawlins. Reporting of adverse drug reactions by hospital pharmacists: pilot scheme. *BMJ* 315: 519 (Published 30 August 1997) or postponed? *J R Coll Phys Lond.*, 1995; 29: 41–9.
14. Sharmila Nirojini P, Rama Rao Nadendla, Valli manalan B, Habeeb Ibrahim AR. Role of Hospital Pharmacists in Reporting Adverse Drug Reactions- A Review. *Archives of Pharmacy Practice*, 2012; 3(3): 197-201.
15. Pushkin R, Frassetto L, Tsouronis C, Segal ES, et al. Improving the reporting of adverse drug reactions in the hospital setting. *Postgrad Med.*, Nov. 2010; 122(6): 154-64.
16. Alvarez-Requejo A, Carvajal A, Be'gaud B, Moride Y, Vega T, et al. Under-reporting of adverse drug reactions. Estimate based on a spontaneous reporting scheme and a sentinel system. *Eur J Clin Pharmacol*, Aug. 1998, 54(60): 483-8.
17. Y Moride, F Hramburu, A Requejo, B Be'gaud. Under-reporting of adverse drug reactions in general practice. *Br J Clin Pharmacol*, Feb. 1997; 43(2): 177-181.
18. Herdeiro MT, Figueiras A, Polónia J, Gestal-Otero JJ. Influence of pharmacist's attitudes on adverse drug reaction reporting: a case-control study in Portugal. *Drug Saf.*, 2006; 29(4): 331-40.
19. Sweis D, Wong IC. A survey on factors that could affect adverse drug reaction reporting according to hospital pharmacist in Great Britain. *Drug Saf.*, Aug. 2000; 23(2): 165-72.
20. Gavaza P, Brown CM, Lawson KA, Rascati KL, et al. Examination of pharmacist's intention to report serious adverse drug events to the Food and Drug Administration. *Br J Clin Pharmacol*, July 2011; 72(1): 143-52.
21. Herdeiro MT, Figueiras A, Polónia J, Gestal-Otero JJ. Influence of pharmacist's attitudes on adverse drug reaction reporting: a case-control study in Portugal. *Drug Saf.*, 2006; 29(4): 331-40.
22. Schlienger RG, Lüscher TF, Haefeli WE, Schoenenberger RA. Academic detailing improves identification and reporting of adverse drug events. *Pharm World Sci.*, 1999; 21(3): 110–5.
23. Yu YM, Lee E, Koo BS, et al. Predictive factors of spontaneous reporting of adverse drug reactions among community pharmacists. *PLoS One.*, 2016; 11(5): e0155517.

24. Green CF, Mottram DR, Rowe P, Brown AM. Attitudes of hospital pharmacists to adverse drug reaction reporting: a qualitative survey. *Int J Pharmacy Prac.*, 1999; 7(4): 247–255.
25. Pagotto C, Varallo FR, Mastroianni PC. Impact of educational interventions on adverse drug events reporting. *Int J Technol Assess Health Care.*, 2013; 29(4): 410–417.
26. Gonzalez-Gonzalez C, Lopez-Gonzalez E, Herdeiro MT, Figueiras A. Strategies to improve adverse drug reaction reporting: a critical and systematic review. *Drug Saf.*, 2013; 36(5): 317–328.
27. Lynn RM, Riding K, McIntosh N. The use of electronic reporting to aid surveillance of ADRs in children: a proof-of-concept study. *Arch Dis Child.*, 2010; 95(4): 262–265.
28. Ortega A, Aguinagalde A, Lacasa C, Aquerreta I, Fernández-Benítez M, Fernández LM. Efficacy of an adverse drug reaction electronic reporting system integrated into a hospital information system. *Ann Pharmacother.*, 2008; 42(10): 1491–1496.